Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARAMINE vs ABILIFY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Direct-acting sympathomimetic amine that stimulates alpha-adrenergic receptors, causing vasoconstriction and increased blood pressure.
Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.
Treatment of hypotension due to certain acute medical conditions (e.g., spinal anesthesia, drug-induced hypotension),Off-label: adjunct in the management of septic shock
Schizophrenia,Bipolar I disorder (acute manic/mixed episodes, maintenance),Major depressive disorder (adjunctive therapy),Irritability associated with autistic disorder,Tourette's disorder
Intravenous infusion: 1-10 mg initially, then 0.5-5 mg/hr titrated to blood pressure. Intramuscular or subcutaneous: 2-10 mg every 2 hours as needed.
Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).
Terminal elimination half-life is 2-4 hours. Clinical context: Requires continuous infusion for sustained blood pressure support.
Aripiprazole: 75 hours; dehydro-aripiprazole: 94 hours. Steady-state reached in ~14 days.
Primarily hepatic via oxidative deamination by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT)
Hepatic metabolism primarily via CYP3A4 and CYP2D6; also by dehydrogenation and N-dealkylation.
Primarily renal: 85% unchanged drug in urine within 24 hours. Biliary/fecal: <5%.
Renal (25% unchanged, 18% as dehydro-aripiprazole) and fecal (55% unchanged and metabolites).
Approximately 50-70% bound to albumin and alpha-1 acid glycoprotein.
>99% bound to albumin and alpha-1-acid glycoprotein.
0.5-1.0 L/kg. Clinical meaning: Indicates extensive distribution into tissues, consistent with a polar catecholamine.
4.9 L/kg (high distribution into tissues).
Intramuscular: 100%; Subcutaneous: 100%; Oral: negligible (<5%) due to extensive first-pass metabolism.
Oral: 87% (tablet and solution); IM: 100%.
No specific dose adjustment guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to reduced clearance.
No dosage adjustment required for renal impairment; not removed by hemodialysis.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to altered metabolism.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) due to limited data.
Intravenous infusion: 0.1-0.2 mg/kg/dose, titrate to effect; maximum 0.5 mg/kg/dose.
Schizophrenia (13-17 years): 2 mg/day, target 10-25 mg/day. Bipolar mania (10-17 years): 2 mg/day, target 10-30 mg/day. Autism irritability (6-17 years): 2 mg/day, target 5-15 mg/day.
Use lower initial doses (e.g., 0.5-1 mg IV) and titrate slowly due to increased sensitivity and risk of hypertension.
Initiate at lower doses (e.g., 2-5 mg/day) and titrate slowly due to increased risk of adverse effects, especially orthostatic hypotension and cognitive decline.
None
Increased risk of death in elderly patients with dementia-related psychosis due to cerebrovascular events.
Risk of extravasation leading to tissue necrosis,Use with caution in patients with hypertension, hyperthyroidism, or cardiovascular disease,May cause bradycardia reflexively,Monitor blood pressure closely during administration
Increased mortality in elderly dementia patients, suicidal thoughts/behaviors, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes (hyperglycemia, dyslipidemia, weight gain), orthostatic hypotension, leukopenia/neutropenia, seizures, body temperature dysregulation, dysphagia, impulse control disorders.
Hypersensitivity to metaraminol or any component,Use with MAO inhibitors (may cause severe hypertensive crisis),Use in patients with pheochromocytoma or severe hypertension
Known hypersensitivity to aripiprazole or any of its excipients.
Avoid tyramine-rich foods (e.g., aged cheeses, cured meats, fermented products) if taking MAOIs, but no specific dietary restrictions for metaraminol itself. Maintain adequate hydration as directed.
Grapefruit juice may increase aripiprazole exposure; avoid concurrent intake. No other significant food interactions. Alcohol can enhance CNS depression; limit or avoid.
FDA Pregnancy Category C. First trimester: Animal studies show fetal abnormalities; no adequate human studies. Second/third trimester: Risk of maternal hypertension, reduced uterine blood flow; may cause fetal bradycardia, hypoxia, or metabolic acidosis. Avoid in eclampsia.
Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and third trimesters: neonates exposed in late pregnancy are at risk for extrapyramidal symptoms (EPS) and withdrawal syndrome including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder.
No human data. M/P ratio unknown. Excretion likely minimal due to high protein binding; exercise caution. Prefer alternative agents.
Aripiprazole is excreted in human breast milk; milk-to-plasma (M/P) ratio is approximately 0.5 to 1.0. Relative infant dose is estimated to be 1-3% of maternal weight-adjusted dose. Limited data; use with caution. Monitor infant for sedation, poor feeding, and abnormal movements.
Increased plasma volume may require higher initial doses. Titrate to effect; monitor for exaggerated pressor response. No fixed dose adjustment; individualize.
No established pharmacokinetic data; however, pregnancy-induced physiological changes (increased plasma volume, renal clearance) may lower aripiprazole levels. Monitor therapeutic efficacy and consider dose adjustment if symptom exacerbation. No specific dose modification guidelines available; titrate based on clinical response and tolerability.
ARAMINE (metaraminol) is a potent vasopressor used primarily for acute hypotension. Monitor blood pressure frequently, ideally via intra-arterial line, as its duration of action is prolonged (up to 1 hour) and may cause rebound hypertension. Avoid extravasation; central line administration preferred. Tachyphylaxis can occur with prolonged use. It is contraindicated in patients with MAOI use within 14 days due to hypertensive crisis risk.
Abilify (aripiprazole) is a partial dopamine agonist, which reduces the risk of extrapyramidal symptoms and hyperprolactinemia compared to full antagonists. Monitor for akathisia, especially during dose titration. QT prolongation risk is lower than with other antipsychotics; use caution in patients with cardiac disease. Avoid use in dementia-related psychosis due to increased mortality. Therapeutic effects may take 2-4 weeks; full response often requires 6-8 weeks.
This medication is given intravenously to raise blood pressure during emergencies.,You will be closely monitored with frequent blood pressure checks and possible arterial line.,Report any chest pain, severe headache, or blurred vision immediately.,Inform your healthcare provider of all medications you take, especially antidepressants.,Do not stop or change the dose without medical advice.
Take exactly as prescribed; do not stop abruptly without consulting your doctor.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol and grapefruit juice as they can alter drug levels.,Report any uncontrolled muscle movements, especially in face or tongue.,Monitor weight and blood glucose regularly as it can cause metabolic changes.,If you miss a dose, take it as soon as you remember unless it's almost time for the next dose; do not double up.,Use effective contraception if of childbearing potential; discuss pregnancy plans with your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARAMINE vs ABILIFY, answered by our medical review team.
ARAMINE is a Vasopressor that works by Direct-acting sympathomimetic amine that stimulates alpha-adrenergic receptors, causing vasoconstriction and increased blood pressure.. ABILIFY is a Atypical antipsychotic that works by Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARAMINE and ABILIFY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARAMINE is: Intravenous infusion: 1-10 mg initially, then 0.5-5 mg/hr titrated to blood pressure. Intramuscular or subcutaneous: 2-10 mg every 2 hours as needed.. The standard adult dose of ABILIFY is: Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARAMINE and ABILIFY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARAMINE is classified as Category C. FDA Pregnancy Category C. First trimester: Animal studies show fetal abnormalities; no adequate human studies. Second/third trimester: Risk of maternal hypertension, reduced uterin. ABILIFY is classified as Category C. Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and thir. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.